Table 3.

Evaluation of bortezomib in combination with other therapies.

Type of therapy	Drug or agent	Cancer	References
Chemotherapy	5-Fluorouracil, cisplatin, paclitaxel, doxorubicin, cyclophosphamide	Breast, lung	Teicher et al [45], 1999
	Melphalan, doxorubicin, dexamethasone	Multiple myeloma	Hideshima et al [15], 2001 Mitsiades et al [50], 2003 Ma et al [20], 2003
	Topoisomerase inhibitor: irinotecan	Colon Pancreatic	Cusack et al [30], 2001 Shah et al [24], 2001
	Gemcitabine	Pancreatic Bladder	Bold et al [48], 2001 Kamat et al [51], 2004
	Pegylated liposomal doxorubicin	Breast	Small et al [52], 2004
	Docetaxel	Pancreatic	Nawrocki et al [53], 2004
	Temozolomide	Melanoma	Amiri et al [49], 2004
Radiation therapy		Breast Colon Prostate	Teicher et al [45], 1999 Russo et al [16], 2001 Pervan et al [54], 2001
Immunotherapy	Daclizumab	Adult T-cell leukemia	Tan and Waldmann [19], 2002
Novel agents	TRAIL/Apo2L	Multiple myeloma, myeloid leukemia, renal	Mitsiades et al [55], 2001 Sayers et al [56], 2003
	HSP90 inhibitor: 17-AAG	Breast	Mimnaugh et al [39], 2004
	HDAC inhibitors: SAHA, sodium butyrate	CML, multiple myeloma, lung	Denlinger et al [40], 2004 Yu et al [57], 2003 Mitsiades et al [58], 2004 Denlinger et al [59], 2004 Pei et al [60], 2004
Transplantation	Allogeneic BMT	Leukemia	Sun et al [61], 2004

HSP = heat shock protein; HDAC = histone deacetylase; CML = chronic myelogenous leukemia; BMT = bone marrow transplantation.